Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05579353

The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Shandong First Medical University

Jinan, Lixia, 250014, China

Location status: Recruiting

Location contact

Jingbo Chen, doctor

CONTACT

[email protected]

15053186972 ext. nothing

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1.18-80 years old.

2.18.5 < BMI < 27.9.

  • The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion criteria

  • Those who refuse to collect samples.
  • Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
  • Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
  • Combining with distant multiple metastases of tumor

Treatment and study plan

nothing

Other

nothing

Primary outcomes

  1. expressional quantity

    Time frame: Through study completion, an average of 2 year

    Expression of CRTC2 in patient samples

Study contacts

Contact information is provided by the study sponsor or research team.

Jingbo Chen, doctor

CONTACT

[email protected]

15053186972 ext. nothing

Sponsors and collaborators

Lead sponsor

Jingbo Chen

Other

Registry information

Official study title

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Oct 13, 2022
Registry last updated
Oct 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.